High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.
about
Damage associated molecular pattern moleculesHMGB1: endogenous danger signalingPlasmacytoid dendritic cells and type I IFN: 50 years of convergent historyHMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cellsCo-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer.Stepwise release of biologically active HMGB1 during HSV-2 infection.The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammationToll-like receptor agonists in cancer therapy.Cancer and inflammation: promise for biologic therapy.Natural selection in a bangladeshi population from the cholera-endemic ganges river deltaHMGB1 in health and disease.Extracellular high mobility group box 1 plays a role in the effect of bone marrow mononuclear cell transplantation for heart failure.The sterile inflammation in the exacerbation of HBV-associated liver injury.Exogenous high-mobility group box 1 protein injection improves cardiac function after myocardial infarction: involvement of Wnt signaling activation.Clinical opportunities in combining immunotherapy with radiation therapy.TLR agonists are highly effective at eliciting functional memory CTLs of effector memory phenotype in peptide immunization.Life after death: targeting high mobility group box 1 in emergent cancer therapies.Is HMGB1 an osteocyte alarmin?Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.Fueling autoimmunity: type I interferon in autoimmune diseases.Tolerogenic plasmacytoid DC.High-mobility group box 1, oxidative stress, and disease.Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity.Danger-associated molecular patterns (DAMPs) in acute lung injury.Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation.HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells.High mobility group box 1 and adenosine are both released by endothelial cells during hypothermic preservation.Exogenous high-mobility group box 1 protein prevents postinfarction adverse myocardial remodeling through TGF-β/Smad signaling pathway.
P2860
Q24564765-8D6B60DC-0A32-4BCE-89AC-C1A9283E9DB4Q24645232-F76FBC53-E0C6-4FC8-A26A-FFBFEA24715AQ27485637-7CE96138-5180-49DD-B1FA-5ADB45EE611AQ28117763-FCD9FF2A-1874-4E1B-B71A-42BDEB31123CQ33693936-E9580329-F245-4266-B0C8-F3C970346819Q33809521-EC8005E8-8C01-4627-940B-CDE52A73DD1AQ33851482-6374B687-B7EB-4FB3-B91A-87B762AB899EQ33918509-FA204F1F-309B-45B6-A774-EEAA0FC01B28Q34139732-1D1D006F-83F3-4A0F-885D-059EC14CF574Q34355363-4A52A485-8D64-4A25-B0CF-0410B2AE3DDCQ34622835-981E1E70-F75F-4780-85FE-9AC07CF50443Q35034878-02875EDE-87BB-4BAA-A4F7-3779E6292876Q35373060-9521AEEB-B191-4C01-B9D4-D911ED447BBDQ36000159-96132D8A-F36E-4BB2-93AD-15E26743BE2EQ36449873-62A07909-E560-4FC6-B931-4E5AF8C020B5Q36539888-D599E794-91DA-44F4-9B51-E3F70661F12EQ36562901-B37BF8F4-2DEA-4EAB-BBE0-F57B56C7485DQ36975910-A883C6B2-77E4-4A22-B6C8-AA8B01D2CDD8Q37229916-E5723EAD-423D-46C0-8EA4-FB68E7BC54CDQ37416120-042076D3-C27A-43AB-8592-770050BE56F5Q37683083-353A30B6-B473-4429-B967-EA3B89F85252Q37802381-67207874-E7AE-4BF8-B0C7-C27A34C0D748Q37956517-F0504836-B3AB-484B-8CFC-AA32B1916F20Q38055437-F3BF0A78-137C-435E-8F58-FF58C52B84AFQ38239650-877AE91A-0857-4010-A878-7495E48A4F11Q38930365-DD5EFE0D-1F31-4130-A296-A97872482F8DQ46701506-C7E7C73C-36F5-4A63-8F3D-E27F4191C0E6Q46733988-D19998A5-EDC3-49D4-973E-A5576C6BA19C
P2860
High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
High mobility group B1 protein ...... ell response to TLR9 agonists.
@en
High mobility group B1 protein ...... ell response to TLR9 agonists.
@nl
type
label
High mobility group B1 protein ...... ell response to TLR9 agonists.
@en
High mobility group B1 protein ...... ell response to TLR9 agonists.
@nl
prefLabel
High mobility group B1 protein ...... ell response to TLR9 agonists.
@en
High mobility group B1 protein ...... ell response to TLR9 agonists.
@nl
P2093
P1476
High mobility group B1 protein ...... ell response to TLR9 agonists.
@en
P2093
Arthur M Krieg
Charles K Brown
David L Bartlett
Herbert J Zeh
Kevin J Tracey
Michael T Lotze
Petar J Popovic
Richard DeMarco
Steven E Winikoff
Z Sheng Guo
P304
P356
10.4049/JIMMUNOL.177.12.8701
P407
P577
2006-12-01T00:00:00Z